Correlation Between mTOR Pathway and Clinical Outcomes in Patients with Well-Differentiated Neuroendocrine Tumors Treated with Everolimus

#513

Introduction: Everolimus has been studied in preclinical and clinical settings, showing it to be active and effective. Tumors exhibiting the constitutively activated phosphatidylinositol-3-kinase-AKT-mTOR (PI3K/AKT/mTOR) pathway, are potentially susceptible to mTOR inhibitors. Even though Everolimus is both an antiproliferative and anti-angiogenic drug, we do not know the possible prognostic or predictive role of p-mTOR pathway.

Aim(s): To determine the expression of some factors of the pathway of p-mTOR in patients treated with Everolimus and to evaluate the possible correlations with the clinical outcomes: response rate (RR), time to progression (TTP), and overall survival (OS).

Materials and methods: We reviewed the clinical records of patients with histological diagnosis of progressive advanced unresectable NETs. The tumors were defined according to WHO 2010 classification. The tissue tumor samples were centrally (IEO) analysed to detect subtype 2 somatostatin receptor, phospho-AKT, phospho-mTOR, phospho-4E-BP1, phospho-p70-S6 kinase, PTEN, mutations of PI3K gene.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Spada F, Pisa E, Lorizzo K, Barberis M, Fazio N,

Keywords: mTOR,